Key Financial Data Of Reporting Company

Daito Pharmaceutical Co., Ltd. - Filing #7289262

Concept As at
2024-11-30
2024-06-01 to
2024-11-30
2023-06-01 to
2024-05-31
As at
2024-05-31
As at
2023-11-30
2023-06-01 to
2023-11-30
Key financial data of reporting company
Business results of reporting company
Net sales
24,584,000,000 JPY
46,895,000,000 JPY
24,110,000,000 JPY
Ordinary profit (loss)
1,470,000,000 JPY
3,923,000,000 JPY
2,314,000,000 JPY
Net assets
52,020,000,000 JPY
52,265,000,000 JPY
52,122,000,000 JPY
Total assets
79,633,000,000 JPY
77,708,000,000 JPY
74,990,000,000 JPY
Basic earnings (loss) per share
59.39
210.00
98.22
Diluted earnings per share
Equity-to-asset ratio
0.653 xbrli:pure
0.670 xbrli:pure
0.692 xbrli:pure
Net cash provided by (used in) operating activities
1,840,000,000 JPY
5,182,000,000 JPY
1,946,000,000 JPY
Net cash provided by (used in) investing activities
-5,287,000,000 JPY
-5,930,000,000 JPY
-3,616,000,000 JPY
Net cash provided by (used in) financing activities
3,964,000,000 JPY
-183,000,000 JPY
2,609,000,000 JPY
Cash and cash equivalents
3,241,000,000 JPY
2,727,000,000 JPY
4,585,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.